The effectiveness of Reslizumab in severe asthma treatment: a real-world experience

Respiratory Research

Table 1 Baseline demographic and clinical characteristics

Patients and disease variables	Baseline (N = 26)
The mean age	52 years (SD ± 13.5).
Mean ACQ-6 score ± SD	3.5 (SD ± 1.1)
Systemic glucocorticoid.	54% were on maintenance oral steroid^a
Mean steroid dose amongst patients on long term glucocorticoid^b	9.3 (SD ± 4.3) mg^b
Mean percent of FEV₁ predicted value (before bronchodilation) + − SD	62% (SD ± 19.9)
Average number of exacerbations^c ± SD	8.3 (SD ± 4.7)
Mean peripheral blood Eosinophils count^d ± SD	0.78 cells X 10⁹/L (SD ± 0.51)

ACQ-6 Asthma Control Questionnaire, FEV1 Forced Expiratory Volume in 1 second, ^aN=14, ^bPrednisolone dose in mg, ^cAverage number of exacerbations per year that required rescue systemic steroids course or increase in the maintenance steroid dose, ^dcells X 10⁹/L

ISSN: 1465-993X